T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products based on its proprietary platform. Its T2 Magnetic Resonance platform enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company offers T2Dx, a bench-top instrument, which has completed a pivotal clinical trial for performing diagnostic tests in sepsis and other applications; and T2Stat, an integrated instrument for hemostasis applications. It is also developing T2Candida panel that has completed a pivotal clinical trial for identifying pathogens associated with sepsis; T2HemoStat panel, which includes a set of hemostasis measurements, including platelet function, clotting time, and clot degradation; and T2Bacteria, a multiplex diagnostic panel that detects the bacterial pathogens associated with sepsis. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.